FDA Bars Avastin's Use As Breast Cancer Treatment

Law360, New York (November 18, 2011, 1:09 PM EST) -- The U.S. Food and Drug Administration on Friday withdrew its approval of blockbuster Genentech Inc. drug Avastin for the treatment of breast cancer, citing its potentially fatal side effects and a lack of proof as to its effectiveness.

FDA Commissioner Margaret A. Hamburg said there was no evidence the drug delayed tumor growth in metastatic breast cancer patients, lengthened their lives or improved their quality of life. The risk of heart failure, organ perforation and other side effects were too great to maintain approval of the...
To view the full article, register now.